March 2021 Br J Cardiol 2021;28:7–10 doi:10.5837/bjc.2021.007
Sarah Maria Birkhoelzer, Elena Cowan, Kaushik Guha
Introduction SARS-CoV-2 has rapidly become a worldwide health emergency. The declaration by the World Health Organisation (WHO) in March 2020 of a global pandemic has underscored the widespread morbidity and mortality caused by the virus. Concerted efforts by healthcare and research communities are ongoing to establish the efficacy and potency of various pharmacotherapeutics. It has been shown that coronavirus disease 2019 (COVID-19) affects multiple organs and has heterogeneous effects on the cardiovascular system. This is also accompanied by enhanced morbidity and mortality in patients with pre-existing cardiovascular disease.1 In urgent e
April 2014 Br J Cardiol 2014;21:79 doi:10.5837/bjc.2014.013 Online First
Jakub Lagan, Louise Cutts, Diane Barker, Peter Currie
Background Hypothyroidism is a common endocrine disorder, which has a variety of effects on the cardiovascular system including decreased cardiac output, increased systemic vascular resistance, accelerated atherosclerosis and rhythm disturbances, such as sinus bradycardia, conduction defects or non-specific ST changes.1,2 Hypothyroidism can also cause prolongation of the QTc interval and ventricular arrhythmias.1 Case presentation A 76-year-old woman was admitted to our hospital with a collapse, and while in the emergency department she sustained a witnessed cardiac arrest secondary to torsades de pointes (TdP) (figure 1). This was terminated
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits